论文部分内容阅读
目的:研究疫苗对胃肠道.恶性肿瘤患者免疫功能的影响。方法:从人外周静脉血中分离单核细胞,人重组粒细胞/巨噬细胞集落刺激因子(rhGM-CSF)和人重组白细胞介素4(rhIL-4)、IL-2、和IFN-γ诱导扩增,CEA相关多肽致敏,促树突状细胞成熟以提高其抗原提呈能力。双相倒置显微镜下观察树突状细胞的形态结构,流式细胞仪检测树突状细胞细胞表型。成熟的树突状细胞经皮下和静脉两种回输途径回输给胃肠道恶性肿瘤患者。观察回输疫苗后一个月、三个月患者细胞免疫及体液免疫的变化。结果:双相倒置显微镜观察,培养第7天的悬浮细胞大部分具有典型树突状细胞形态特征,细胞表面粗糙,有大量皱折和不规则突起。培养第7--15d增殖最明显,培养15d,树突状细胞纯度达85%以上。流式细胞仪检测树突状细胞中度表达CDla,高表达CD86,CD40,HLA-DR。病人的细胞免疫及体液免疫指标CD4、CD8、CD3、CD4/CD8、IgG、IgM明显提高,IgA略有提高,CEA有所下降。结论:树突状细胞疫苗给胃肠道晚期恶性肿瘤患者回输后一个月、三个月,患者细胞免疫CD4,CD8和体液免疫IgG,IgM具有显著提高,IgA有一定的提高
Objective: To study the effect of vaccine on immune function in patients with gastrointestinal cancer. Methods: Monocytes, human recombinant granulocyte / macrophage colony stimulating factor (rhGM-CSF) and human recombinant interleukin 4 (IL-4), IL-2 and IFN- γ were isolated from human peripheral blood Induced amplification, CEA-related peptide sensitization, promote dendritic cell maturation to enhance its antigen-presenting ability. The morphology of dendritic cells was observed under inverted microscope, and the dendritic cell phenotypes were detected by flow cytometry. Mature dendritic cells are delivered transdermally and intravenously to patients with gastrointestinal cancer. Observed after transfusion of vaccine one month, three months of patients with cellular and humoral immune changes. Results: In the inverted phase contrast microscope, most of the suspension cells cultured on the 7th day showed typical dendritic cell morphological features. The cell surface was rough with a lot of folds and irregular protrusions. During the 7th-15th day of culture, the proliferation was the most obvious. After cultured for 15 days, the purity of dendritic cells reached more than 85%. Flow cytometry detected dendritic cells moderately expressed CDla, high expression of CD86, CD40, HLA-DR. CD4, CD8, CD3, CD4 / CD8, IgG, IgM of patients with cellular immunity and humoral immunity were significantly increased, IgA slightly increased, CEA decreased. CONCLUSION: The dendritic cell vaccine has a significant increase in CD4, CD8 and IgG, IgM and IgA in patients with advanced gastrointestinal cancer one month and three months after the transfusion,